Literature DB >> 9781949

Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.

T Onda1, H Yoshikawa, T Yasugi, M Mishima, S Nakagawa, M Yamada, K Matsumoto, Y Taketani.   

Abstract

BACKGROUND: Patients with epithelial ovarian carcinoma upstaged from Stage I/II to Stage IIIC based on lymph node involvement are known to have poor prognoses. The authors investigated whether systematic aortic and pelvic lymphadenectomy would affect the prognoses of these patients.
METHODS: During the period 1987-1996, 103 patients in Stage I-III underwent optimal cytoreductive surgery with systematic aortic and pelvic lymphadenectomy at initial surgery. All patients except for those in Stage IA received adjuvant cisplatin-based chemotherapy after surgery. Of 67 patients with intraperitoneal tumors limited to the pelvis, 14 were upstaged to Stage III based on lymph node positivity (Group A). The authors compared the survival of Group A patients with that of 53 patients who had intraperitoneal tumors limited to the pelvis and negative lymph nodes (Group B), and also with that of 36 patients who had intraperitoneal tumors beyond the pelvis irrespective of lymph node status (Group C).
RESULTS: The 5-year survival of Group A patients in Stage III based only on lymph node positivity had fairly good survival, although it was not significantly different from that of Group B patients in Stage I/II (84% vs. 96%, P=0.107). Group A had much better 5-year survival than Group C patients who were considered to be Stage III because they had intraperitoneal tumors beyond the pelvis (84% vs. 26%, P=0.042).
CONCLUSIONS: Relatively good survival was observed for patients with intraperitoneal tumors limited to the pelvis and lymph node involvement who underwent systematic aortic and pelvic lymphadenectomy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781949

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

Review 1.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Should we modify the current FIGO staging system for stage IIIC ovarian cancer?

Authors:  Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

Review 3.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

4.  Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Authors:  Cornelia Bachmann; Robert Bachmann; Bernhard Kraemer; Sara Yvonne Brucker; Anette Staebler; Falko Fend; Ralf Rothmund; Diethelm Wallwiener
Journal:  Mol Clin Oncol       Date:  2016-08-05

5.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

Review 6.  Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists.

Authors:  Tsukasa Saida; Yumiko Oishi Tanaka; Koji Matsumoto; Toyomi Satoh; Hiroyuki Yoshikawa; Manabu Minami
Journal:  Jpn J Radiol       Date:  2015-12-22       Impact factor: 2.374

7.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

8.  What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Authors:  Bunja J Rungruang; Austin Miller; Thomas C Krivak; Neil S Horowitz; Noah Rodriguez; Chad A Hamilton; Floor J Backes; Linda F Carson; Michael Friedlander; David G Mutch; Michael J Goodheart; Krishnansu S Tewari; Robert M Wenham; Michael A Bookman; G Larry Maxwell; Scott D Richard
Journal:  Cancer       Date:  2016-11-16       Impact factor: 6.860

9.  Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.

Authors:  Allison Gockley; Alexander Melamed; Amy J Bregar; Joel T Clemmer; Michael Birrer; John O Schorge; Marcela G Del Carmen; J Alejandro Rauh-Hain
Journal:  Obstet Gynecol       Date:  2017-03       Impact factor: 7.661

10.  Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.

Authors:  Su-Jin Baek; Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.